Loren Data's SAM Daily™

FBO DAILY ISSUE OF AUGUST 03, 2008 FBO #2442
SOLICITATION NOTICE

68 -- Genomic DNA Sample Kits

Notice Date

8/1/2008
 

Notice Type

Modification/Amendment
 

NAICS

325413 — In-Vitro Diagnostic Substance Manufacturing
 

Contracting Office

Department of Health and Human Services, National Institutes of Health, National Heart, Lung and Blood Institute, Rockledge Dr. Bethesda, MD, Office of Acquisitions, 6701 Rockledge Dr RKL2/6100 MSC 7902, Bethesda, Maryland, 20892-7902
 

ZIP Code

20892-7902
 

Solicitation Number

NHLBI-PB-AR-2008-213-RCO
 

Response Due

8/15/2008 5:00:00 PM
 

Archive Date

8/30/2008
 

Point of Contact

Rosie C Owens,, Phone: (301) 435-7920, Kathleen Marsden,, Phone: 301.435.0364
 

E-Mail Address

rowens@mail.nih.gov, marsdenk@nhlbi.nih.gov
 

Small Business Set-Aside

N/A
 

Description

This is a combined synopsis/solicitation for commercial items prepared in accordance with the format in FAR 12.6 as supplemented with additional information included in this notice. This announcement constitutes the only solicitation and a separate written solicitation will not be issued. This solicitation number is NHLBI-PB-(AR)-2008-213-RCO and is issued as a Request for Quotation (RFQ). The solicitation will include all applicable provisions and clauses in effect through Federal Acquisition Circular 05-26 (as of 06/12/2008). The North American Industry Classification (NAICS) Code is 325413 and the business size standard is 500. This acquisition is being conducted using Simplified Acquisition Procedures in accordance with FAR Part 13. However, this solicitation is set aside for small businesses. It is the intent of the National Heart, Lung, and Blood Institute’s (NHLBI) Consolidated Operations Acquisition Centers (COAC) on behalf of National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) to procure the services from Illumina Inc., 9885 Towne Center Drive, San Diego, Ca. 92121 for the following product: Human CNV370-Quad DNA Analysis Kits- catalog#wg-311-1401 and wg-311-1403. Background: Protocol Number: 94-AR-0105 Project Entitled: Genetics and Pathophysiology of Familial Mediterranean Fever and Related Disorders, “ BEHCET’S DISEASE” Summary: This study is designed to explore the genetics involved in diseases of intermittent fever, including familial Mediterranean fever, TRAPS, hyper-IgD syndrome, and related diseases. The following individuals may be eligible for this study: 1) patients 5 years of age and older with known or suspected familial Mediterranean fever, TRAPS, hyper-IgD syndrome or related disorders; 2) relatives of these patients; 3) healthy, normal volunteers 18 years of age or older; and 4) healthy patients with gout 18 years of age or older who are taking colchicine. In addition, in order to satisfy the requirements of the Behçet's disease protocol and ensure the data generated can be incorporated into an extensive pre-existing database derived using the Human CNV370-Quad DNA Analysis Kits, the proposed project must adhere to the conditions, genomic DNA, the purposed protocol must adhere to the conditions, quality of needed supplies required of integrity of experiment. The purpose of this requirement is to process the next 800 samples of genomic DNA as a continuation our genome-wide complex genetics analysis of Behcet’s disease. Through this process data is combined with data already collected; therefore, the product and platform cannot be changed. Only the Illumina beadstation automated processing robotics and automated sample scanning, for which this product can be used. Changing variable under protocol #94-AR-0105, is not possible. Researchers are exploring possible genetic, bacterial, and viral causes of Behçet's disease as well as improved drug treatment. For example, genetic studies show strong association of the gene HLA-B51 with the disease, but the exact role of this gene in the development of Behçet's is uncertain. Researchers hope to identify genes that increase a person's risk for developing Behçet's disease. Studies of these genes and how they work may provide new understanding of the disease and possibly new treatments. a.)Researchers are also investigating factors in the environment, such as bacteria or viruses, which may trigger Behçet's disease. They are particularly interested in whether Streptococcus, the bacterium that causes strep throat, is associated with Behçet's disease. Many people with Behçet's disease have had several strep infections. In addition, researchers suspect that herpes virus type 1, a virus that causes cold sores, may be associated with Behçet's disease. Finally, researchers are identifying other medicines to better treat Behçet's disease. TNF inhibitors are a class of drugs that reduce joint inflammation by blocking the action of a substance called tumor necrosis factor. Although serious side effects have been reported for TNF inhibitors, they have shown some promise in treating Behçet's disease. Examples of TNF inhibitors include etanercept and infliximab. Also, interferon alpha, a protein that helps fight infection, has shown promise in treating Behçet's disease. Thalidomide, which is believed to be a TNF inhibitor, appears effective in treating severe mouth sores, but its use is experimental and side effects are a concern. Thalidomide is not used to treat women of childbearing age because it causes severe birth defects. Interested parties may identify their interest and capability to respond to the requirement or submit proposals. This notice of intent is not a request for competitive proposals. However, all proposals received within 15 days after publication of this synopsis will be considered by the Government. Delivery date: Thirty days after receipt of purchase order The offeror must include a completed copy of the following provisions: 1) FAR Clause 52.212-1 Instructions to Offerors Commercial; 2) FAR Clause 52.212-2, Evaluation Commercial Items. As stated in FAR Clause 52.212-2 (a), The Government will award a contract resulting from this solicitation to the responsible offeror whose offer conforming to the solicitation will be most advantageous to the Government, price and other factors considered. The following factors shall be used to evaluate offers: Technical Evaluation and Price. 3) FAR Clause 52.212-3, Offeror Representations and Certifications Commercial Items; 4) FAR Clause 52.212-4, Contract Terms and Conditions Required To Implement Statues or Executive Orders Commercial Items, Contract Terms and Conditions Commercial Items; and 5) FAR Clause 52.212-5, Contract Terms and Conditions Required to Implement Statutes or Executive Orders Commercial Items Deviation for Simplified Acquisitions. This notice of intent is not a request for competitive proposals. The resulting acquisition will be entered into pursuant to the acquisition authority set forth in FAR 6.302-1 and 41 U.S.C. 253(c) (1) and HHSAR 306-302-1. Only one responsible source and no other supplies or services will satisfy agency requirements. The sole source determination is based on the need to continue on-going experiment; changing variable would disrupt the outcome of the experiment. Therefore, an award to any other source is neither feasible nor practical. This notice of intent is not a request for competitive quotations however; all responses received within 15 days from the date of publication of this synopsis will be considered by the Government. Interested parties may identify their interest and capability to respond to the requirement or submit proposals. However, the determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received will normally be considered solely for the purpose of determining whether to conduct a competitive procurement. The offeror must include in their quotation, the unit price, the list price, shipping and handling cost. Note: In order to receive an award from the NHLBI contractors must have a valid registration in the Central Contractor Registration (CCR) www.ccr.gov and registered in Dun and Bradstreet (DUNS), the Taxpayer Identification and the certification of business size www.bpn.gov. The clauses are available in full text at http://www.arnet.gov/far. Quotations will be due fifteen (15) calendar days from the publication date of this synopsis or by August 15, 2008, 5pm, Eastern Standard Time. Responses will only be accepted if dated and signed by an authorized company representative. Interested vendors capable of furnishing the government with the item specified in this synopsis should submit their quotation to the below address. Inquires to this notice, referencing number NHLBI-PB-(AR)-2008-213-RCO, submitted in writing to the National Heart, Lung and Blood Institute, Office of Acquisition, Procurement Branch, 6701 Rockledge Drive, Suite 6128, Bethesda, Maryland 20892-7902. Attention: Ms. Rosie C. Owens, Contract Specialist. If submitted electronically: Email: Rosie C. Owens, Contract Specialist rowens@nhlbi.nih.gov or Ms. Kathleen Marsden, Contracting Officer marsdenk@nhlbi.nih.gov. Faxed copies will not be accepted.
 

Web Link

FedBizOpps Complete View
(https://www.fbo.gov/?s=opportunity&mode=form&id=760f06ccfe4721ebff22ead70b754a18&tab=core&_cview=1)
 

Place of Performance

Address: Bethesda, Maryland, 20892-0001, United States

Zip Code: 20892-0001
 

Record

SN01628865-W 20080803/080801221422-760f06ccfe4721ebff22ead70b754a18 (fbodaily.com)
 

Source

FedBizOpps Link to This Notice
(may not be valid after Archive Date)

---

| FSG Index  |  This Issue's Index  |  Today's FBO Daily Index Page |